We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




RDW Blood Test Can Predict Mortality and Re-Admission Among Elderly, Hospitalized Patients

By LabMedica International staff writers
Posted on 25 May 2022
Print article
Image: Red blood cell distribution width predicts prognoses in elderly, hospitalized patients (Photo courtesy of Pexels)
Image: Red blood cell distribution width predicts prognoses in elderly, hospitalized patients (Photo courtesy of Pexels)

Red cell distribution width (RDW), an index for variation of red blood cell size, has been proposed as a potential marker for poorer outcomes in several aging-related diseases and conditions. The biological mechanisms linking greater variability of RBC size and adverse health-related outcomes are not known, however emerging evidence supports the use of RDW as a marker for biologic aging, disease vulnerability, oxidative stress and chronic inflammation. Now, new research has found that higher RDW is associated with increased rates of in-hospital mortality and hospital re-admission among older (>60) patients.

In a retrospective analysis, investigators at Sutter’s California Pacific Medical Center (CPMC, Davis, CA, USA) studied 94,617 patients aged >60 who were hospitalized between January 2013 to December 2017 at Sutter Health. A total of 167,292 admissions were included. The RDW was measured during hospital admission and categorized with 1% intervals. The primary outcome was the rate of in-hospital mortality; secondary outcomes included 30-day re-admission rate and length of hospital stay.

Results showed the overall in-hospital mortality rate was 6.3%. As the RDW value increased, the rate of in-hospital mortality increased from 2.7% for the lowest RDW category to 12.2% in the highest category (p-trend <0.001). The overall 30-day re-admission rate after discharge was 12.5% and the rate of 30-day readmission also increased with increasing RDW categories (7.4% in the lowest group vs. 15.8% in the highest group, p-trend <0.001). Patients with the highest RDW values at admission stayed 1.5–2.0 times longer in the hospital than patients with lower RDW values who were admitted for the same causes.

“Greater variability of red blood cell size is significantly associated with worse prognosis in hospitalized elderly patients, indicating higher mortality, greater risk of early re-admission and longer hospital stay days. Risk stratification strategies for hospitalized elderly should include RDW value,” said Steve Cummings, M.D., lead author of the study, director of the SFCC and a principal investigator at CPMC.

“Predicting the risk of mortality and re-admission are critical for in-patient care. An accurate risk classification strategy for patients can also improve outcomes in clinical practice,” added Warren Browner, M.D., co-author of the study and CEO of CPMC. “However, there are no strong predictors of mortality or early re-admission that can be applied across multiple aging-related diseases. These findings provide the potential of RDW value, one of the most common laboratory tests that are performed for most hospitalized patients, as a biomarker for poorer prognosis or vulnerability in hospitalized elderly patients.”

Related Links:
CPMC 

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Cytomegalovirus Real-Time PCR Test
Quanty CMV Virus System
New
Pipet Controller
Stripettor Pro

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.